A phase I, single-centre, non-randomised, open-label, pharmacokinetic and mass balance study of orally administered [14C]-AZD9291 in healthy male volunteers
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2015
Price : $35 *
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 15 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov .
- 25 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 30 May 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.